The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Aponvie
Aprepitant · APREPITANT 32 mg/4.4mL · Emulsion · Intravenous · Heron Therapeutics, Inc.
NDC 47426-0401-10 · 10 VIAL, GLASS in 1 CARTON / 4.4 mL in 1 VIAL, GLASS · NDA · View full market →
One drug, every price
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
ⓘ How this was built
Data sources
- CMS NADAC (pharmacy acquisition, weekly)
- CMS Part B ASP quarterly payment limits
- CMS Maximum Fair Prices (IRA negotiated, NDC-level)
- Medicare Part D Spending by Drug (data.cms.gov, name-matched)
- VA FSS / Big4 federal contract prices (va.gov, twice monthly)
- ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
- California SB-17 WAC filings (list price, per package)
Method
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
- Medicare Part B pays (ASP+6%)$2.00per billing unit (1 MG)HCPCS J8502 · Jul 1, 2026
- Part D plans paid (avg)$96.14per dosage unitgross, before rebates — matched by drug name · 2024
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$624.60
Reported to Texas DSHS · 2026 annual filing · Heron Therapeutics, Inc
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicare Part B (ASP)
Payment limit per 1 MG
$1.998
HCPCS J8502 · Jul 1, 2026 quarter · typically ASP + 6%
Medicaid spend (2025)
$63,090
1,359 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for aprepitant (other) in the next 90 days
OAI inspection at a producing facility (24 months) · sole-source market · 1 Class I/II recall(s) in 12 months
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Where it's made
- Alcami Carolinas CorporationUnited Statespack
- Alcami Carolinas CorporationUnited Statesanalysis
- Alcami Carolinas CorporationUnited Statesmanufacture
- api manufacture
- Integrated Commercialization Solutions, LLCUnited Statespack
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $649.22 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- NDA216457
- TE code
- —
- Approval date
- Sep 16, 2022
- Patents / exclusivity
- 14 patents, 0 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| patent | 10953018 | Sep 18, 2035 |
| patent | 10624850 | Sep 18, 2035 |
| patent | 9974794 | Sep 18, 2035 |
| patent | 9808465 | Sep 18, 2035 |
| patent | 9561229 | Sep 18, 2035 |
| patent | 11744800 | Sep 18, 2035 |
| patent | 11878074 | Sep 18, 2035 |
| patent | 10500208 | Sep 18, 2035 |
| patent | 9974793 | Sep 18, 2035 |
| patent | 12290520 | Sep 18, 2035 |
| patent | 12115254 | Sep 18, 2035 |
| patent | 9974742 | Sep 18, 2035 |
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Aprepitant (Emulsion)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Heron Therapeutics, Inc. | APREPITANT 32 mg/4.4mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Aponvie — NDC 47426-0401-10," retrieved September 3, 2026, https://drugdashboards.com/drug/47426040110.
Free to cite with attribution — see how the data is put together.